Jeffrey Sherman serves as the Chief Financial Officer (CFO) at NeoGenomics, Inc., a leading cancer diagnostics and pharma services company. In his role, Sherman oversees the financial operations and strategy of the company, ensuring its continued growth and profitability. With a wealth of experience in the financial sector, Sherman has been instrumental in guiding NeoGenomics through its expansion and development phases. Before joining NeoGenomics, Sherman held various senior financial positions at several prominent companies. His career began at Ernst & Young, where he honed his skills in auditing and financial management. He later moved on to roles such as Vice President of Finance at Laboratory Corporation of America and Senior Vice President and CFO at Bio-Reference Laboratories. These positions equipped him with a deep understanding of the healthcare and diagnostics industry, making him an ideal fit for his current role at NeoGenomics. Sherman's strategic financial planning and leadership have been pivotal in driving NeoGenomics' success, including the company's acquisitions and integrations that have broadened its service offerings and market reach. Under Sherman's guidance, NeoGenomics has seen significant growth and has solidified its position as a leader in the cancer diagnostics field. His commitment to excellence and innovation in financial management has not only supported the company's operational goals but also enhanced its reputation among investors and stakeholders. Sherman's vision for NeoGenomics includes continuing to leverage advanced technologies and strategic partnerships to further the company's mission of improving patient outcomes through precision medicine.